Clinical trial is halted for lupus drug Riquent

Monitoring board: treatment 'futile'

Lupus patients across the nation were distraught by the news yesterday that La Jolla Pharmaceutical stopped the clinical trial of its drug Riquent.

An independent monitoring board looked at preliminary trial data and determined that using the drug was “futile” in stopping deadly symptoms of lupus, the company said in a one-paragraph news release.